Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2006 Mar 23;354(12):1264-72.
doi: 10.1056/NEJMoa054013.

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

Jonathan C Cohen  1 , Eric Boerwinkle, Thomas H Mosley Jr, Helen H Hobbs
Affiliations
Free article
Comparative Study

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

Jonathan C Cohen et al. N Engl J Med. .
Free article

Abstract

Background: A low plasma level of low-density lipoprotein (LDL) cholesterol is associated with reduced risk of coronary heart disease (CHD), but the effect of lifelong reductions in plasma LDL cholesterol is not known. We examined the effect of DNA-sequence variations that reduce plasma levels of LDL cholesterol on the incidence of coronary events in a large population.

Methods: We compared the incidence of CHD (myocardial infarction, fatal CHD, or coronary revascularization) over a 15-year interval in the Atherosclerosis Risk in Communities study according to the presence or absence of sequence variants in the proprotein convertase subtilisin/kexin type 9 serine protease gene (PCSK9) that are associated with reduced plasma levels of LDL cholesterol.

Results: Of the 3363 black subjects examined, 2.6 percent had nonsense mutations in PCSK9; these mutations were associated with a 28 percent reduction in mean LDL cholesterol and an 88 percent reduction in the risk of CHD (P=0.008 for the reduction; hazard ratio, 0.11; 95 percent confidence interval, 0.02 to 0.81; P=0.03). Of the 9524 white subjects examined, 3.2 percent had a sequence variation in PCSK9 that was associated with a 15 percent reduction in LDL cholesterol and a 47 percent reduction in the risk of CHD (hazard ratio, 0.50; 95 percent confidence interval, 0.32 to 0.79; P=0.003).

Conclusions: These data indicate that moderate lifelong reduction in the plasma level of LDL cholesterol is associated with a substantial reduction in the incidence of coronary events, even in populations with a high prevalence of non-lipid-related cardiovascular risk factors.

PubMed Disclaimer

Comment in

Similar articles

See all similar articles

Cited by

  • Mapping hyperlipidemia in young adulthood to coronary risk: importance of cumulative exposure and how to stay young.
    Martin SS, Michos ED. Martin SS, et al. Circulation. 2015 Feb 3;131(5):445-7. doi: 10.1161/CIRCULATIONAHA.114.014433. Epub 2015 Jan 26. Circulation. 2015. PMID: 25623154 Free PMC article. No abstract available.
  • Chromosome Xq23 is associated with lower atherogenic lipid concentrations and favorable cardiometabolic indices.
    Natarajan P, Pampana A, Graham SE, Ruotsalainen SE, Perry JA, de Vries PS, Broome JG, Pirruccello JP, Honigberg MC, Aragam K, Wolford B, Brody JA, Antonacci-Fulton L, Arden M, Aslibekyan S, Assimes TL, Ballantyne CM, Bielak LF, Bis JC, Cade BE, Do R, Doddapaneni H, Emery LS, Hung YJ, Irvin MR, Khan AT, Lange L, Lee J, Lemaitre RN, Martin LW, Metcalf G, Montasser ME, Moon JY, Muzny D, O'Connell JR, Palmer ND, Peralta JM, Peyser PA, Stilp AM, Tsai M, Wang FF, Weeks DE, Yanek LR, Wilson JG, Abecasis G, Arnett DK, Becker LC, Blangero J, Boerwinkle E, Bowden DW, Chang YC, Chen YI, Choi WJ, Correa A, Curran JE, Daly MJ, Dutcher SK, Ellinor PT, Fornage M, Freedman BI, Gabriel S, Germer S, Gibbs RA, He J, Hveem K, Jarvik GP, Kaplan RC, Kardia SLR, Kenny E, Kim RW, Kooperberg C, Laurie CC, Lee S, Lloyd-Jones DM, Loos RJF, Lubitz SA, Mathias RA, Martinez KAV, McGarvey ST, Mitchell BD, Nickerson DA, North KE, Palotie A, Park CJ, Psaty BM, Rao DC, Redline S, Reiner AP, Seo D, Seo JS, Smith AV, Tracy RP, Vasan RS, Kathiresan S, Cupples LA, Rotter JI, Morrison AC, Rich SS, Ripatti S, Willer C; NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium; FinnGen; Peloso GM. Natarajan P, et al. Nat Commun. 2021 Apr 12;12(1):2182. doi: 10.1038/s41467-021-22339-1. Nat Commun. 2021. PMID: 33846329 Free PMC article.
  • A register-based cohort study on the effectiveness and Safety of anti-PCSK9 treatment in persons with hyperlipidemia.
    Andersen MA, Helms Andreasen A, Evi Bang L, Jimenez-Solem E, Petersen TS. Andersen MA, et al. Commun Med (Lond). 2024 Oct 7;4(1):193. doi: 10.1038/s43856-024-00611-x. Commun Med (Lond). 2024. PMID: 39375518 Free PMC article.
  • Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia.
    Bell DA, Hooper AJ, Watts GF, Burnett JR. Bell DA, et al. Vasc Health Risk Manag. 2012;8:651-9. doi: 10.2147/VHRM.S28581. Epub 2012 Nov 28. Vasc Health Risk Manag. 2012. PMID: 23226021 Free PMC article. Review.
  • Matching taxpayer funding to population health needs: not so simple.
    Lauer MS, Gordon D, Olive M. Lauer MS, et al. Circ Res. 2015 Apr 10;116(8):1301-3. doi: 10.1161/CIRCRESAHA.114.305893. Circ Res. 2015. PMID: 25858063 Free PMC article. No abstract available.
See all "Cited by" articles

Publication types

MeSH terms